{"entity":{"id":"nct07595276","kind":"trial","name":"Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Stat","aka":[],"tldr":"A phase 3 trial of cetuximab in colorectal cancer, run by Taizhou Mabtech Pharmaceutical Co.,Ltd, not yet recruiting.","summary":"Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. is a phase 3, randomised interventional study registered as NCT07595276 by Taizhou Mabtech Pharmaceutical Co.,Ltd, with a registry enrolment figure of 608 participants, started 2026-06-01 and due to reach its primary completion in 2029-10-01. Interventions recorded: Enlituo®; Erbitux®. Conditions listed: Colorectal Cancer. Primary outcome: Objective Response Rate (ORR) within 16 weeks assessed by BIRC according to RECIST v1.1 criteria. Colorectal eligibility wording from the registry: \"* Participants with histologically and/or cytologically confirmed locally advanced/metastatic colorectal cancer\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07595276","url":"https://clinicaltrials.gov/study/NCT07595276"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["cetuximab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07595276","phase":"3","setting":"A Multicenter, Randomized, Double-blind, Phase III Clinical Study Evaluating the Efficacy and Safety of Enlituo® Plus FOLFOX Versus Erbitux® Plus FOLFOX as First-line Treatment for Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","enrolled":608,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07595276/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}